Valneva SE, a prominent biotechnology company within the health care sector, has been making significant strides in the development and commercialization of vaccines targeting infectious diseases. Based in Nantes, France, Valneva SE is listed on the NYSE Euronext Paris and operates in multiple countries. The company’s primary focus is on creating vaccines for diseases such as Japanese encephalitis, cholera, and diarrhea caused by enterotoxigenic Escherichia coli, with its marketed products including IXIARO/JESPECT and Dukoral.
Valneva SE’s innovative approach leverages its proprietary EB66 vaccine production cell line and IC31 adjuvant, which are integral to its vaccine development technologies. These technologies are utilized in collaboration with biopharmaceutical and pharmaceutical companies, as well as academic institutions, through various service and licensing agreements. This collaborative model enhances Valneva’s ability to advance its vaccine candidates for diseases like clostridium difficile, Lyme disease, chikungunya, and Zika.
Financially, Valneva SE has experienced fluctuations in its stock performance. As of May 20, 2026, the company’s close price was recorded at 2.473 EUR, with a 52-week high of 5.415 EUR on August 17, 2025, and a 52-week low of 2.135 EUR on May 3, 2026. The company’s market capitalization stands at 464,940,000 EUR, and it has a price-to-earnings ratio of -3.72, reflecting its current financial standing.
In recent market commentary, Valneva SE was highlighted among various stocks discussed by traders, indicating its relevance in the broader investment landscape. While no specific financial details were provided in the commentary, the mention of Valneva SE alongside companies like Nel ASA and several technology firms suggests that it is part of the ongoing conversation about sectors attracting investor interest.
Valneva SE, which went public on June 29, 2007, continues to be a key player in the biotechnology industry, focusing on addressing global health challenges through its vaccine development efforts. For more information, interested parties can visit the company’s website at www.valneva.com .
